NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
Clinical Trials
6 trialsNCT05798507 2025-12-15
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT04720417 2025-07-15
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT06495125 2025-04-17
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT03681483 2024-07-10
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00773526 2016-11-02
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
Hoffmann-La Roche
Phase 1 Completed